Tuvonralimab and Iparomlimab before surgery for bile duct cancer
Part of Cancer, Digestive system clinical trials.
This trial tests two immunotherapy drugs (Tuvonralimab and Iparomlimab) given before surgery to shrink bile duct cancers that are borderline removable. The goal is to make the tumor easier to remove completely and improve outcomes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have bile duct cancer that is considered borderline removable (the doctor thinks it might be possible to remove it with complex surgery).
- You have not had any previous treatment for your cancer (no chemotherapy, radiation, or other drugs).
- Your cancer is locally advanced without spreading to distant organs (like the liver or lungs).
- You are in good overall health (able to do daily activities without help, with a performance status of 0 or 1).
- Your blood counts and organ function (kidneys, liver) are within acceptable ranges.
- You agree to use effective contraception if applicable, and are not pregnant or breastfeeding.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a combination of three drugs (ivonescimab, liposomal irinotecan, and 5-FU/LV) in people with bile duct or gallbladder cancer that hasn't been treated yet. The goal is to shrink the tumor enough so that it can be removed with surgery.
This trial tests a combination of two immunotherapy drugs, chemotherapy, and a targeted therapy to shrink bile duct or gallbladder cancers that are advanced but might be removable with surgery. The goal is to see if this approach can make surgery possible and improve outcomes.
This trial tests a new drug combination given before surgery to shrink bile duct cancer tumors, potentially making surgery more successful. It is for patients whose cancer is locally advanced or has spread to only a few places.
This trial tests a combination of immunotherapy drugs, radiation therapy, and a targeted therapy drug before and after surgery for people with intermediate-stage liver cancer that can be surgically removed. The goal is to see if this approach can shrink tumors and improve outcomes.
This trial tests a new immunotherapy drug combined with standard chemotherapy as a first treatment for advanced bile duct or gallbladder cancer. It may help your immune system fight the cancer while chemotherapy attacks the tumor directly.
This trial tests two drugs given before surgery to people with liver cancer that has a high chance of coming back. The goal is to see if the drugs can shrink the tumor and lower the risk of recurrence.
Hear when a new Biliary Tract Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.